Silexion Therapeutics Corp. (NASDAQ: SLXN) ("Silexion" or the "Company"), a clinical-stage biotechnology company pioneering RNA interference (RNAi) therapies for KRAS-driven cancers, today announced ...

Milestone supports advancement of PRF’s drop-less ocular drug-delivery platform into next-stage U.S. clinical development for ...

Silexion Therapeutics Corp. (NASDAQ: SLXN) ("Silexion" or the "Company"), a clinical-stage biotechnology company pioneering RNA interference ...

Bookings in the first quarter increased 21% year-over-year. First quarter bookings included seven large deals, which are ...

Adjusted EBITDA -- $32 million, representing a 580 basis point year-over-year margin expansion to 16% of sales. Segment ...

UCLA researchers created a single-cell map of the developing human neocortex in Down syndrome during a critical window of ...

PRF Technologies Ltd. (Nasdaq: PRFX) ("PRF" or the "Company"), a clinical-stage specialty pharmaceutical company focused on reformulating established ...

SAS AI Navigator offers a unified view of whatever models and tools a team is already using, including LLMs, AI agents and ...

St. Petersburg, it’s the city I grew up in, right here in South St. Pete, where the church I went to as a kid is still the ...

Q1 2026 Earnings Call April 28, 2026 5:00 PM EDTCompany ParticipantsStephen Haymore - Director of Investor RelationsAli El-Haj ...

The 2026 Annual Member Meeting of the Innovative Optical and Wireless Network Global Forum (IOWN Global Forum) in Sydney recognized its progress and shared its latest plans to deliver the digital ...

Adjusted EBITDA -- $30 million, more than doubling from $14 million, attributed to operational improvements, acquisition ...